share_log

翰森制药(03692.HK):HS-10504片获临床试验通知书

Hanson Pharmaceuticals (03692.HK): HS-10504 tablets received clinical trial notice

Gelonghui Finance ·  Apr 3 06:35

Gelonghui, April 3 | Hanson Pharmaceutical (03692.HK) announced that the Class 1 new drug HS-10504 tablets independently developed by the company's subsidiary Jiangsu Hausen Pharmaceutical Group Co., Ltd. and Shanghai Hanson Biomedical Technology Co., Ltd. have obtained a clinical trial notice approved and issued by the China National Drug Administration to treat advanced non-small cell lung cancer. The specific indications are to be determined after clinical trials.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment